Principal Investigator: Deborah  Stephens
Keywords: CLL Lymphoma Department: Hematology
IRB Number: 00105515
Specialty: Hematology/BMT
Sub Specialties:
Recruitment Status: Recruiting

Contact Information

Deborah  Stephens
lindsay.carpenter@hci.utah.edu
8015874756

Brief Summary

Primary Objectives

a. To compare the complete response rate at 6 cycles after randomization as defined by centrally read PET/CT (integral biomarker) of 2 targeted therapeutic regimens (obinutuzumab + TGR-1202 or obinutuzumab + lenalidomide) with obinutuzumab + CHOP in patients with early relapsing or refractory follicular lymphoma.

Secondary Objectives

a. (Primary Translational Medicine Objective): To validate the prognostic association of the m7-FLIPI model, demonstrating that the population of follicular lymphoma patients who respond poorly to chemoimmunotherapy are enriched for having a high-risk m7-FLIPI score, and that the score is associated with progression-free survival (integrated biomarker).

b. To estimate the 30 month sustained complete response rate (CR30) defined by centrally read PET/CT with each of the regimens in this early relapsing or refractory follicular lymphoma population.

c. To estimate best response at 12 cycles of therapy, progression free survival, duration of response and overall survival with each of the combinations in early relapsing or refractory follicular lymphoma.

d. To evaluate the adverse effects of each of the regimens in early relapsing or refractory follicular lymphoma.

e. To evaluate the predictive performance of non-invasive genotyping (m7-FLIPI in circulating tumor DNA) of plasma at study entry relative to standard tumor genotyping (m7-FLIPI) of formalin-fixed paraffin-embedded tumor tissue.

f. To evaluate the association between the detection of active lymphoma by PET-CT and the detection of circulating tumor DNA in plasma at baseline, after 6 and 12 cycles, and at 30 months after initiation of study therapy.

Inclusion Criteria

Disease Related Criteria

a. Patients must have follicular lymphoma (Grade I, II or IIIa) confirmed at initial diagnosis and at relapse with identifiable FDG avid disease on PET/CT.

Patients that have involvement with large cell lymphoma are not eligible.

c. Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration.

d. Patients must have bone marrow biopsy performed within 42 days prior to registration.

All disease must be assessed and documented on the S1608 FDG-PET/CT Assessment Form.

 

Prior/Concurrent Therapy Criteria

a. Patients must meet all the following:

• Patients must have either failed to achieve a complete remission, or must have relapsed within 2 years after completing first line bendamustine-containing chemoimmunotherapy (including an anti-CD20 monoclonal antibody), as measured from the last dose of bendamustine. Relapsed patients must not have received any intervening chemotherapy.

• Patients must have received at least 3 cycles of bendamustine as first line therapy. (Note that no minimum dose of bendamustine is required.)

• Patients who additionally received any maintenance anti-CD-20 antibody based therapy or consolidative radioimmunotherapy within 2 years of the last dose of the bendamustine therapy are eligible.

• Involved field or involved site radiation is not considered a line of therapy.

• Patients who previously received anthracycline based therapy are excluded.

Examples of eligible 1st line treatment regimens (note this list is not all inclusive):Consistent with other randomized trials, 19% of patients in the rituximab arm had progressed or died at 2 years, while only 12% had similar events in the obinutuzumab arm.

Three-year overall survival rates were similar at 94% and 92% for the obinutuzumab and rituximab arms respectively. (37)

These two targeted agent/anti-CD20 antibody doublets represent efficacious combinations warranting further study in refractory FL. Further, adequate safety data are available allowing for further study in an intergroup setting. Each combination will be evaluated by its respective complete remission rate, the ability to act as a platform for future combinatorial investigations and whether a molecular signature can be used to predict treatment responses.

• Bendamustine rituximab x 4 cycles

• Bendamustine bortezomib rituximab x 6 cycles followed by rituximab maintenance

• Bendamustine obinutuzumab x 3 cycles

b. For all forms of systemic therapy, patients must have completed therapy at least 21 days prior to registration. Patients must have completed any radioimmunotherapy at least 84 days prior to registration. Patients must have recovered from all treatment related toxicities from these therapies prior to registration.

Specimen Submission Criteria

a. Patients must have blood and tissue specimens collected prior to registration and submitted for translational medicine as outlined in Section 15.1. See Section 15.1e for information regarding pre-ordering of specimen kits.

With patient consent, residuals from the mandatory submission will be banked for future research.

Clinical/Laboratory

a. Patients must be ≥ 18 years of age.

b. All patients must have a Zubrod performance status of 0, 1 or 2 (see Section 10.4).

c. Patients must have adequate bone marrow function as defined in the protocol.

d. Patients must have adequate renal function as defined in the protocol.

e. Patients must have adequate hepatic function obtained within 28 days prior to registration as defined in the protocol.

f. Patients must have an echocardiogram (ECHO) or MUGA scan within 42 days prior to registration with a cardiac ejection fraction ≥ 45%.

g. Patients with Hepatitis B Virus infection must have undetectable HBV on suppressive therapy and no evidence of HBV-related hepatic damage.

Patients with Hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable HVC or related hepatic damage.

Patients with known HIV infection are eligible if they meet all of the following criteria in addition to the other protocol eligibility criteria:

• Patient must have no history of AIDS-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy. On study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low.

• Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia.

• Patient must have serum HIV viral load of < 200 copies/mm3

• Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy. (Recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine.)

• Protease inhibitors and once daily formulations containing cobicistat are NOT allowed due to potential pharmacokinetic interactions with leukemia therapy.

• Stavudine and zidovudine are NOT allowed because of overlapping toxicity with protocol therapy.

h. Patients must be able and willing to receive prophylaxis with daily aspirin, low molecular weight heparin, factor X inhibitors or Warfarin if randomized to lenalidomide. Patients must also be willing to receive pneumocysitis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, atovaquone or inhaled pentamadine, in the event that they are randomized to TGR-1202. Patients unable or unwilling to take any listed prophylaxis are NOT eligible.

i. Patients must be able to discontinue CYP2C9 substrates with a narrow therapeutic index (e.g. warfarin, phenytoin), if randomized to TGR-1202. Patients must discontinue such agents at least 1 week or 5 half-lives prior to beginning protocol therapy (whichever is longer). A list of 2C9 substrates is available at http://medicine.iupui.edu/clinpharm/ddis/main-table/. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference.

j. No second prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for three years.

k. Patients must have a complete history and physical examination within 28 days prior to registration.

l. Patients must have the following components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration:

• Age

• LDH

• Number of nodal groups involved (see Appendix 18.7)

• Serum or plasma hemoglobin

• Ann Arbor Stage

Additionally, patients must have beta-2-microglobulin collected at time of registration.

m. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 – 14 days and again within 24 hours prior to starting Cycle 1 of lenalidomide. Further, they must either commit to complete abstinence (True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or post-ovulation methods] and withdrawal are not acceptable methods of contraception.) from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, while taking lenalidomide, during dose interruptions, and for at least 28 days after the last dose of lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy. A FCBP is female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). All patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure. (See Appendix 18.1: Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, and also Appendix 18.2: Lenalidomide Education and Counseling Guidance Document).

NOTE: Patients not randomized to receive lenalidomide will not be required to undergo serial pregnancy testing or lenalidomide counseling after registration.

 

Regulatory Criteria

a. Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

b. As a part of the OPEN registration process (see Section 13.3 for OPEN access instructions) the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

Exclusion Criteria

Disease Related Criteria

b. Patients must not have clinical evidence of central nervous system involvement by lymphoma, since the proposed treatment strategies are not designed to address CNS involvement adequately. If performed, any laboratory or radiographic tests performed to assess CNS involvement must be negative.

Prior/Concurrent Therapy Criteria

c. Patients must not have any prior treatment with any PI3K inhibitor, or lenalidomide.

Specimen Submission Criteria

Note that patients without adequate diagnostic specimens will not be eligible.